PCSK9 Inhibition for Therapeutic Decision-Making: Assessing the Value

J Am Coll Cardiol. 2020 May 12;75(18):2309-2311. doi: 10.1016/j.jacc.2020.03.037.
No abstract available

Keywords: acute coronary syndromes; alirocumab; cholesterol; cost-effectiveness; economic analysis.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome*
  • Antibodies, Monoclonal, Humanized
  • Cost-Benefit Analysis
  • Humans
  • Proprotein Convertase 9*

Substances

  • Antibodies, Monoclonal, Humanized
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • alirocumab